|
You are comparing CCSI to early stage biotechs - that's like comparing Bill Clinton to...oh well, why stoop that low. Look, good biotech firms have a technological platform which hopefully can create many products. That is different than a drug or biotech firm who has a drug for this or that. It is the difference between a hit or miss strategy and having a pipeline that grows. CCSI has no technological platform. If you look in their own fed filings, you will see they have inventory of unsold Colormate units going back years and years. The market size statements of the peanut butter guy on this thread were lies. They were based on a per use revenue to CCSI. If CCSI had the only device available, they might be able to do that with some health care providers. But, by the end of this year, there will be another device on the market that does the exact same thing as the CCSI device does, for bilirubin testing. If you are a hospital, and if SpectRx is willing to sell you the device outright, vs. CCSI selling you the device and then asking for money every time the device is used, who would you rather buy it from. If you add ease of use, (where, by the way, the CCSI device is actually inferior), how does that tip the scales? As for the stocks, CCSI market cap is twice that of SPRX. SPRX truly believes that larger potential exists in the glucose monitoring area, not bilirubin. They regard bilirubin as an area that gives them some diversity which lessens their dependence on glucose monitoring, where many companies are working their butts off to develop systems where diabetics don't have to prick their fingers to take blood samples. Stating market sizes of X or Y are amusing, but misleading when a medical device company and it's hypesters state the market size in terms of cost to the end user, in this case, the family that has a baby that is getting a heel-stick test. Perhaps MacFarland and peanut butter boy believe CCSI will sell devices directly to parents of newborns? Maybe babies will be flown into CCSI headquarters in NY for testing. Maybe Macfarland spent too much time as a cosmetician and was exposed to nail polish fumes which distorted her thinking. |
